2026 Michael B. Atkins: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	137	1852	1724	1055	970	748	117444

Overview

Michael B. Atkins is affiliated with Georgetown University in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Economics and Econometrics.

The scientist's work concentrates on several key topics such as Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, CAR-T cell therapy research, Renal and related cancers, Economic and Financial Impacts of Cancer, and Melanoma and MAPK Pathways.

Frequent publication venues for Michael B. Atkins include:

Journal of Clinical Oncology
Journal for ImmunoTherapy of Cancer
Annals of Oncology
Clinical Cancer Research
Cancer Research

Their recent papers demonstrate active involvement in clinical oncology and cancer research, including:

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (2020), The Lancet Oncology
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma (2023), New England Journal of Medicine
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade (2020), Cancer Cell
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma (2020), Annals of Oncology
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 (2022), Journal of Clinical Oncology

Michael B. Atkins collaborates frequently with several researchers, including:

David F. McDermott
Brian I. Rini
Toni K. Choueiri
Opeyemi A. Jegede
Elizabeth R. Plimack

Best Publications

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

14371
Citations
Final Version of 2009 AJCC Melanoma Staging and Classification

Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

5434
Citations
Comprehensivemolecular characterization of clear cell renal cell carcinoma

Chad J. Creighton;Margaret Morgan;Preethi H. Gunaratne;Preethi H. Gunaratne;David A. Wheeler

4161
Citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

3808
Citations
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

3343
Citations
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

Charles M. Balch;Antonio C. Buzaid;Seng-Jaw Soong;Michael B. Atkins

3292
Citations
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

Charles M. Balch;Seng-Jaw Soong;Jeffrey E. Gershenwald;John F. Thompson

2902
Citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

2649
Citations
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Michael B. Atkins;Michael T. Lotze;Janice P. Dutcher;Richard I. Fisher

2497
Citations
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

2208
Citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

2152
Citations
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

1787
Citations
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Geoffrey T Gibney;Louis M Weiner;Michael B Atkins

1535
Citations
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Michael B. Atkins;Manuel Hidalgo;Walter M. Stadler;Theodore F. Logan

1181
Citations
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

1172
Citations
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

1145
Citations
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55

Herbert Tilg;Elizabeth Trehu;Michael B. Atkins;Charles A. Dinarello

1135
Citations
Management of cutaneous melanoma.

Hensin Tsao;Michael B Atkins;Arthur J Sober

1100
Citations
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

1087
Citations
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

1030
Citations

Frequent Co-Authors

David F. McDermott Beth Israel Deaconess Medical Center

Toni K. Choueiri Harvard University

Sabina Signoretti Brigham and Women's Hospital

James W. Mier Beth Israel Deaconess Medical Center

Brian I. Rini Vanderbilt University Medical Center

Jeffrey A. Sosman Northwestern University

F. Stephen Hodi Harvard University

John M. Kirkwood University of Pittsburgh

Mario Sznol Yale University

Igor Puzanov Roswell Park Cancer Institute

External Links

Personal website of Michael B. Atkins

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Those aspiring to advance their careers in medicine or healthcare have several online degree options beyond traditional medical school. Programs such as the cheapest mha online programs allow professionals to move into healthcare management roles and gain essential leadership skills while studying affordably.

For nurses aiming to reach the highest clinical expertise, pursuing the cheapest dnp (Doctor of Nursing Practice) programs online is a cost-effective way to earn an advanced practice degree and expand your career impact.

Pharmacists and those interested in pharmaceuticals can consider the best online pharmacy school options. These allow working professionals to earn an accredited PharmD degree with flexible schedules.

Additionally, for those drawn to the intersection of technology and healthcare, online schools for health information management offer pathways to careers managing medical data, security, and patient information.

Exploring these online programs can widen your career opportunities in healthcare while offering flexible study and affordable tuition options.